Exploratory IPF survival analysis 1,2

Esbriet (pirfenidone) achieved a numerical difference in all-cause mortality in three phase 3 trials

No statistically significant difference over the study and follow-up period (up to 120 weeks for available patients)

ASCEND, CAPACITY 004, and CAPACITY 006 exploratory survival analysis vs placebo

Cumulative risk of all-cause mortality through study and follow-up (120 weeks)

CI=confidence interval; HR=hazard ratio.

Multinational, randomized, double-blind, placebo-controlled studies vs placebo 2,14

  • Primary FVC endpoint was measured at 52 weeks for ASCEND and at 72 weeks for CAPACITY 004 and CAPACITY 006 2
  • All-cause mortality was assessed over the study duration and available follow-up, irrespective of cause of death and whether patients continued treatment after study primary endpoint 2